Developer docs
API playgroundTry for free, no card

Search company profiles

Branded Legacy

Full company profile

uuid00052d8

Namestring
Branded Legacy
Legal namestring
Bio Legacy Evaluative Group
Company typeenum
Public
Founded yearint
1981
Descriptiontext

Branded Legacy, Inc. (OTC Pink: BLEG) is a publicly traded holding company headquartered in Melbourne, Florida. Through December 2025 the company operated a portfolio of acquired subsidiaries spanning plant-based pharmaceuticals (Sycamore BioPharma, MariJ Pharmaceuticals), intranasal drug delivery R&D (BioLegacy Evaluative Group — naloxone spray and an air-driven delivery device at the FDA Pre-ANDA stage), sober-social retail (Pau Hana Kava Bar, contributing approximately $125,000 in Q3 revenue), and digital services (Rocket Web Development and Design). The company's stated go-to-market combined consumer retail, wholesale/distributor licensing for CBD across multiple states, pharma distribution through healthcare providers, and direct enterprise sales.

In December 2025, shareholder Dr. Jamie Forrest acquired a controlling interest and executed a complete restructuring: all prior subsidiaries were divested, legacy management was replaced, and approximately $2 million in legacy convertible debt was retired. Jeffery Robison was appointed CEO and Sole Director in April 2026 and announced a strategic pivot toward acquiring multiple AI technology companies targeting healthcare diagnostics, manufacturing automation and supply chain optimization, and retail personalization. A 1-for-2000 reverse stock split became effective June 2, 2026.

As of the input data, Branded Legacy is an operating but effectively pre-revenue public shell with 1–10 employees and no active product-generating subsidiaries. The company's monetizable assets consist of its listed equity instrument, $1 million line of credit, and stated intent to consummate AI acquisitions; commercial credibility for the AI strategy rests on future M&A execution rather than existing technical capability.

Short descriptiontext

Branded Legacy, Inc. (OTC: BLEG) is a publicly traded Melbourne, Florida-based holding company that divested all prior biotech, wellness, and digital subsidiaries in December 2025 and is now repositioning as a serial acquirer of AI technology companies serving healthcare, manufacturing, and retail verticals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCharlotte, United States
HQ citystring
Charlotte
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI healthcare solutions, pharmaceutical development, intranasal drug delivery, manufacturing automation, retail personalization
Industry3 codes
PRIMARYCRADAMAG
Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYHLAIAJAC
OTC & Consumer Health Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYCRADAMAJ
Sleep, Stress & Mood OTC (Sleep Aids, Melatonin OTC, Calm/Stress Relief)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI-Powered Enterprise Solutions
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Kava Bar Operations (Pau Hana)
TypeOne Time License
Description

Revenue generated from kava bar operations including beverage sales. The company posted over $125,000 in third-quarter revenues and plans to expand through acquisition of additional high-performing locations.

globenewswire.com
2Biotechnology and Pharmaceutical Development
TypeLicensing Royalties
Description

Revenue from development and potential commercialization of plant-based pharmaceuticals, CBD products, and drug delivery systems. Includes licensing of intellectual property and operational licenses across multiple states.

prnewswire.com
3CBD and Wellness Products
TypeHardware Sales
Description

Revenue from CBD and wellness industry operations including physical assets, intellectual property, operational tools, and mobile processing units across multiple states.

finance.yahoo.com
4Web Development Services
TypeProfessional Services
Description

Revenue from Rocket Web Development and Design (RWDD) subsidiary providing digital capabilities and web solutions to subsidiaries and clients.

prnewswire.com
5AI Technology Solutions
TypeSubscription Recurring
Description

Revenue from AI-driven solutions and services targeting healthcare, manufacturing, and retail industries with transformative efficiencies.

brandedlegacy.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Branded Legacy, Inc. (OTC: BLEG) is a publicly traded holding company focused on AI technology solutions for the healthcare, manufacturing, and retail industries, acquired and integrated through a strategic acquisition-based growth model. The company additionally develops pharmaceutical products, most notably an intranasal naloxone spray for opioid overdose reversal supported by a proprietary air-driven, needle-free intranasal drug delivery device platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Global kava market growing from $1.6 billion to $3.0 billion by 2033 at 9.3% CAGR
Product overview1 text field

Branded Legacy, Inc. (OTC: BLEG) is a biotechnology holdings company that underwent a complete restructuring in December 2025 under new leadership by shareholder Dr. Jamie Forrest. All previous subsidiaries were divested. The company is now strategically focused on acquiring multiple AI tech companies, targeting select industries that stand to gain from AI adoption. The current product portfolio includes BioLegacy Evaluative Group's intranasal drug delivery technologies, specifically the intranasal naloxone spray and air-driven intranasal drug delivery device, which represent the company's active pharmaceutical development initiatives aimed at addressing the opioid crisis.

Product and service2 records
1Intranasal Naloxone Spray
CategoryPharmaceuticals
Description

Intranasal naloxone spray developed to rapidly reverse opioid overdoses, designed for use by first responders, healthcare providers, and community distribution programs targeting the opioid crisis.

2Air-Driven Intranasal Drug Delivery Device
CategoryDrug Delivery Devices
Description

Proprietary air-driven, needle-free intranasal drug delivery device platform intended to deliver pharmaceuticals such as naloxone without injection, targeted at healthcare providers, emergency responders, and pharmaceutical partners.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Botany Evolution LLC
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Strategic partner in $150 million kava manufacturing investments as part of the global kava root extract market development. Both companies are key players in the emerging plant-based anxiety and stress-relief solutions market.

persistencemarketresearch.com
2CuraScientific Corp.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Strategic partner in $150 million kava manufacturing investments as part of the global kava root extract market development. Collaboration focused on meeting rising consumer interest in plant-based wellness solutions.

persistencemarketresearch.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-24
Description

Branded Legacy Inc acquired Pau Hana Kava Bar as a subsidiary. The acquisition contributes over $125,000 in quarterly revenues with plans for expansion through a roll-up strategy of additional high-performing kava bars, focusing on the sober-social and functional beverage movement in Florida and beyond.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-12
Description

Acquisition of Sycamore BioPharma, Inc., a developer of plant-based pharmaceuticals, which expanded Branded Legacy's assets, inventory, and clinical trials capabilities. The acquisition included appointment of Dr. Mark T. Hamann as Director of Clinical Trials to support pharmaceutical development and FDA approval processes.

5MariJ Pharmaceuticals, Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-05
Description

Largest acquisition to date involving extensive assets and operational licenses across multiple states. Deal includes physical assets, intellectual property, operational tools, and mobile processing units designed to enhance expansion in the CBD and wellness industry, significantly boosting operational capacity and geographic reach.

finance.yahoo.com
6Rocket Web Development and Design (RWDD)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-08-15
Description

Acquisition of Rocket Web Development and Design to enhance digital capabilities and support Branded Legacy's strategic focus on expanding web solutions for subsidiaries and clients.

prnewswire.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Small-cap pharma with innovative specialty therapeutics in development. Comparable as a sub-scale public pharma navigating FDA pathways.

TypeEmerging player
Description

Micro-cap public health company that has undergone multiple strategic pivots and acquisitions. Comparable in scale and pattern of repeated restructuring under new leadership.

TypeDirect peer
Description

Small-cap specialty pharmaceutical company commercializing prescription and consumer health products including intranasal therapies. Comparable scale, business model, and target markets.

TypeEmerging player
Description

Small-cap biotech pivoting business focus with limited operating revenue. Comparable as a micro-cap public shell undergoing strategic reset with new management.

TypeDirect peer
Description

Manufacturer of Narcan, the leading intranasal naloxone spray for opioid overdose reversal. Most directly comparable competitor to Branded Legacy's intranasal naloxone development program.

TypeEmerging player
Description

Small-cap clinical pharma with proprietary intranasal and drug-delivery programs. Comparable as a micro-cap pharma pursuing innovative delivery methods.

TypeDirect peer
Description

Generic injectable and intranasal pharmaceutical manufacturer, including a competing naloxone nasal spray. Comparable as a small-cap specialty pharma with intranasal drug delivery focus.

TypeEmerging player
Description

Small-cap specialty pharma developing and commercializing novel therapeutics. Comparable in scale and specialty pharma orientation.

9Virpax Pharmaceuticals
TypeEmerging player
Description

Clinical-stage small-cap pharma developing novel drug delivery platforms including intranasal formulations. Comparable as a sub-scale pharma with proprietary delivery technology.

TypeEmerging player
Description

Small-cap diagnostics and specialty pharma with OTC and point-of-care products. Comparable as a micro-cap public health-products company.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Branded Legacy

AI-Powered Enterprise Solutionsbrandedlegacy.com

Branded Legacy, Inc. (OTC: BLEG) is a publicly traded Melbourne, Florida-based holding company that divested all prior biotech, wellness, and digital subsidiaries in December 2025 and is now repositioning as a serial acquirer of AI technology companies serving healthcare, manufacturing, and retail verticals.

What Branded Legacy does

Branded Legacy, Inc. (OTC Pink: BLEG) is a publicly traded holding company headquartered in Melbourne, Florida. Through December 2025 the company operated a portfolio of acquired subsidiaries spanning plant-based pharmaceuticals (Sycamore BioPharma, MariJ Pharmaceuticals), intranasal drug delivery R&D (BioLegacy Evaluative Group — naloxone spray and an air-driven delivery device at the FDA Pre-ANDA stage), sober-social retail (Pau Hana Kava Bar, contributing approximately $125,000 in Q3 revenue), and digital services (Rocket Web Development and Design). The company's stated go-to-market combined consumer retail, wholesale/distributor licensing for CBD across multiple states, pharma distribution through healthcare providers, and direct enterprise sales.

In December 2025, shareholder Dr. Jamie Forrest acquired a controlling interest and executed a complete restructuring: all prior subsidiaries were divested, legacy management was replaced, and approximately $2 million in legacy convertible debt was retired. Jeffery Robison was appointed CEO and Sole Director in April 2026 and announced a strategic pivot toward acquiring multiple AI technology companies targeting healthcare diagnostics, manufacturing automation and supply chain optimization, and retail personalization. A 1-for-2000 reverse stock split became effective June 2, 2026.

As of the input data, Branded Legacy is an operating but effectively pre-revenue public shell with 1–10 employees and no active product-generating subsidiaries. The company's monetizable assets consist of its listed equity instrument, $1 million line of credit, and stated intent to consummate AI acquisitions; commercial credibility for the AI strategy rests on future M&A execution rather than existing technical capability.

Branded Legacy firmographics

Firmographics
Name
Branded Legacy
Legal name
Bio Legacy Evaluative Group
Website
https://brandedlegacy.com
Company type
Public
Founded year
1981
Operating status
Operating
Headcount range
1–10 employees
Short description
Branded Legacy, Inc. (OTC: BLEG) is a publicly traded Melbourne, Florida-based holding company that divested all prior biotech, wellness, and digital subsidiaries in December 2025 and is now repositioning as a serial acquirer of AI technology companies serving healthcare, manufacturing, and retail verticals.
Ownership category
akta.pro rank

Branded Legacy industry classification

Industry
Product category
AI-Powered Enterprise Solutions
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRADAMAG
Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYHLAIAJAC
OTC & Consumer Health Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYCRADAMAJ
Sleep, Stress & Mood OTC (Sleep Aids, Melatonin OTC, Calm/Stress Relief)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • AI healthcare solutions
  • Pharmaceutical development
  • Intranasal drug delivery
  • Manufacturing automation
  • Retail personalization

Where Branded Legacy is headquartered

Location

Headquarters

HQ city
Charlotte
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Branded Legacy business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Kava Bar Operations (Pau Hana): Revenue generated from kava bar operations including beverage sales. The company posted over $125,000 in third-quarter revenues and plans to expand through acquisition of additional high-performing locations.
  2. Biotechnology and Pharmaceutical Development: Revenue from development and potential commercialization of plant-based pharmaceuticals, CBD products, and drug delivery systems. Includes licensing of intellectual property and operational licenses across multiple states.
  3. CBD and Wellness Products: Revenue from CBD and wellness industry operations including physical assets, intellectual property, operational tools, and mobile processing units across multiple states.
  4. Web Development Services: Revenue from Rocket Web Development and Design (RWDD) subsidiary providing digital capabilities and web solutions to subsidiaries and clients.
  5. AI Technology Solutions: Revenue from AI-driven solutions and services targeting healthcare, manufacturing, and retail industries with transformative efficiencies.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Branded Legacy product offering

Product offering

Core offering

Branded Legacy, Inc. (OTC: BLEG) is a publicly traded holding company focused on AI technology solutions for the healthcare, manufacturing, and retail industries, acquired and integrated through a strategic acquisition-based growth model. The company additionally develops pharmaceutical products, most notably an intranasal naloxone spray for opioid overdose reversal supported by a proprietary air-driven, needle-free intranasal drug delivery device platform.

Product overview

Branded Legacy, Inc. (OTC: BLEG) is a biotechnology holdings company that underwent a complete restructuring in December 2025 under new leadership by shareholder Dr. Jamie Forrest. All previous subsidiaries were divested. The company is now strategically focused on acquiring multiple AI tech companies, targeting select industries that stand to gain from AI adoption. The current product portfolio includes BioLegacy Evaluative Group's intranasal drug delivery technologies, specifically the intranasal naloxone spray and air-driven intranasal drug delivery device, which represent the company's active pharmaceutical development initiatives aimed at addressing the opioid crisis.

Differentiator

Problem solved

Functional benefit

Products and services

  • Intranasal Naloxone Spray Intranasal naloxone spray developed to rapidly reverse opioid overdoses, designed for use by first responders, healthcare providers, and community distribution programs targeting the opioid crisis.
  • Air-Driven Intranasal Drug Delivery Device Proprietary air-driven, needle-free intranasal drug delivery device platform intended to deliver pharmaceuticals such as naloxone without injection, targeted at healthcare providers, emergency responders, and pharmaceutical partners.

Quantifiable outcome

  • Global kava market growing from $1.6 billion to $3.0 billion by 2033 at 9.3% CAGR

Companies that use Branded Legacy

Customer profile

Segments3 records

Ideal customer profiles3 records

Branded Legacy technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Branded Legacy partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • Botany Evolution LLCminorStrategic or Co-development Partner · 7 April 2026Strategic partner in $150 million kava manufacturing investments as part of the global kava root extract market development. Both companies are key players in the emerging plant-based anxiety and stress-relief solutions market.
  • CuraScientific Corp.minorStrategic or Co-development Partner · 7 April 2026Strategic partner in $150 million kava manufacturing investments as part of the global kava root extract market development. Collaboration focused on meeting rising consumer interest in plant-based wellness solutions.
  • Pau Hana Kava BarcoreStrategic or Co-development Partner · 24 November 2025Branded Legacy Inc acquired Pau Hana Kava Bar as a subsidiary. The acquisition contributes over $125,000 in quarterly revenues with plans for expansion through a roll-up strategy of additional high-performing kava bars, focusing on the sober-social and functional beverage movement in Florida and beyond.
  • Sycamore BioPharma, Inc.coreStrategic or Co-development Partner · 12 March 2024Acquisition of Sycamore BioPharma, Inc., a developer of plant-based pharmaceuticals, which expanded Branded Legacy's assets, inventory, and clinical trials capabilities. The acquisition included appointment of Dr. Mark T. Hamann as Director of Clinical Trials to support pharmaceutical development and FDA approval processes.
  • MariJ Pharmaceuticals, Inc.coreStrategic or Co-development Partner · 5 December 2023Largest acquisition to date involving extensive assets and operational licenses across multiple states. Deal includes physical assets, intellectual property, operational tools, and mobile processing units designed to enhance expansion in the CBD and wellness industry, significantly boosting operational capacity and geographic reach.
  • Rocket Web Development and Design (RWDD)minorStrategic or Co-development Partner · 15 August 2023Acquisition of Rocket Web Development and Design to enhance digital capabilities and support Branded Legacy's strategic focus on expanding web solutions for subsidiaries and clients.

Scale indicators9 records

Recent moves7 records

Expansion highlights4 records

Branded Legacy competitors and assessment

Company assessment

Emerging players

  • Tarsus Pharmaceuticals: Small-cap pharma with innovative specialty therapeutics in development. Comparable as a sub-scale public pharma navigating FDA pathways.
  • Zomedica Pharmaceuticals: Micro-cap public health company that has undergone multiple strategic pivots and acquisitions. Comparable in scale and pattern of repeated restructuring under new leadership.
  • Enveric Biosciences: Small-cap biotech pivoting business focus with limited operating revenue. Comparable as a micro-cap public shell undergoing strategic reset with new management.
  • Tonix Pharmaceuticals: Small-cap clinical pharma with proprietary intranasal and drug-delivery programs. Comparable as a micro-cap pharma pursuing innovative delivery methods.
  • Adamis Pharmaceuticals: Small-cap specialty pharma developing and commercializing novel therapeutics. Comparable in scale and specialty pharma orientation.
  • Virpax Pharmaceuticals: Clinical-stage small-cap pharma developing novel drug delivery platforms including intranasal formulations. Comparable as a sub-scale pharma with proprietary delivery technology.
  • Chembio Diagnostics: Small-cap diagnostics and specialty pharma with OTC and point-of-care products. Comparable as a micro-cap public health-products company.

Direct peers

  • Aytu BioPharma: Small-cap specialty pharmaceutical company commercializing prescription and consumer health products including intranasal therapies. Comparable scale, business model, and target markets.
  • Emergent BioSolutions: Manufacturer of Narcan, the leading intranasal naloxone spray for opioid overdose reversal. Most directly comparable competitor to Branded Legacy's intranasal naloxone development program.
  • Amphastar Pharmaceuticals: Generic injectable and intranasal pharmaceutical manufacturer, including a competing naloxone nasal spray. Comparable as a small-cap specialty pharma with intranasal drug delivery focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Branded Legacy social profiles

Digital presence

Branded Legacy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Branded Legacy leadership team

Management profile

Number of profiles

Profiles1 record

Branded Legacy funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Branded Legacy M&A and investment

M&A and investment

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Branded Legacy

What does Branded Legacy do?

Branded Legacy, Inc. (OTC: BLEG) is a publicly traded holding company focused on AI technology solutions for the healthcare, manufacturing, and retail industries, acquired and integrated through a strategic acquisition-based growth model. The company additionally develops pharmaceutical products, most notably an intranasal naloxone spray for opioid overdose reversal supported by a proprietary air-driven, needle-free intranasal drug delivery device platform.

Is Branded Legacy a public or private company?

Branded Legacy is a public company. It is classified as public and is currently operating.

When was Branded Legacy founded?

Branded Legacy was founded in 1981. It employs 1 to 10 people.

Where is Branded Legacy based?

Branded Legacy is headquartered in Charlotte, United States, in the North America region.

How does Branded Legacy make money?

Five revenue lines are on record. Kava Bar Operations (Pau Hana) is the primary driver. The others are biotechnology and Pharmaceutical Development, CBD and Wellness Products, web Development Services and AI Technology Solutions.

Who are Branded Legacy's main competitors?

Emerging players on record are Tarsus Pharmaceuticals, Zomedica Pharmaceuticals, Enveric Biosciences, Tonix Pharmaceuticals, Adamis Pharmaceuticals, Virpax Pharmaceuticals and Chembio Diagnostics. Direct peers are Aytu BioPharma, Emergent BioSolutions and Amphastar Pharmaceuticals.

Does Branded Legacy have an API?

No public API is recorded for Branded Legacy.

What industry is Branded Legacy in?

Branded Legacy's product category is AI-Powered Enterprise Solutions. Its primary akta.pro industry code is CRADAMAG, Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays), with a secondary code of HLAIAJAC, OTC & Consumer Health Distributors. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireBranded Legacy, Inc. (OTC: BLEG) Finalizes Acquisition of Autonomous Defense CompanyBranded Legacy, Inc. acquired Bletchley Robotics, a Canadian developer of layered autonomous defense systems. The company's initial focus is the LADI-Hornet interceptor drone, targeting $2,000–$8,000 per unit, with plans for UGV and close-range defense layers. The company expects further acquisitions and a name change in coming months.Persistence Market ResearchKava Root Extract Market Size & Growth Analysis, 2033The global kava root extract market is forecast to grow from US$ 1.6 billion in 2026 to US$ 3.0 billion by 2033, representing a compound annual growth rate of 9.3%, driven by rising consumer interest in plant-based anxiety and stress-relief solutions. Asia Pacific leads the market with approximately 41% share, supported by traditional consumption in Pacific Island nations and strong export infrastructure, while North America emerges as the fastest-growing region. Key market developments include strategic extraction agreements, bulk product launches, and $150 million manufacturing investments by companies such as Branded Legacy, Botany Evolution LLC, and CuraScientific Corp., though regulatory restrictions in several European countries continue to constrain market expansion.GlobeNewswireBranded Legacy, Inc. (OTC: BLEG) Successfully Negotiates Retirement of Four Additional Convertible Notes, Preventing Potential Dilution of Hundreds of Millions of SharesBranded Legacy, Inc. announced the retirement of four legacy convertible notes, preventing potential dilution of hundreds of millions of shares. The notes, including three aged over two years and one maturing in September 2026, were retired on favorable terms. Since December 2025, the company has eliminated $1,078,500 in legacy convertible debt.GlobeNewswireBranded Legacy, Inc. Announces Successful Retirement of Legacy Convertible Debt as New Management Focuses on Balance Sheet Optimization and OTC Yield Sign RemovalBranded Legacy, Inc. (OTC: BLEG) announced the successful elimination of approximately $1 million in legacy convertible debt inherited from previous management through direct negotiations with debt holders who had already realized substantial returns. The debt retirement provides an immediate material positive impact on the company's balance sheet by eliminating associated liabilities, substantially reducing future dilution risks, and increasing financial flexibility for shareholders. The new leadership team, led by Dr. Jamie Forrest, is actively working with OTC Markets Group to satisfy remaining requirements for removing the Yield Sign from the company's ticker symbol.GlobeNewswireBranded Legacy, Inc. Announces Complete Management Overhaul and Strategic Reset Under New LeadershipDr. Jamie Forrest acquired controlling interest in Branded Legacy, Inc. (OTC: BLEG) and immediately executed a complete management overhaul, removing all prior officers and directors and fully divesting all legacy subsidiaries. The company expects to issue approximately 300 million shares upon conversion of pre-existing convertible instruments and is conducting a forensic accounting review of historical share issuances and related-party transactions. Dr. Forrest, who is also a fellow at the University of British Columbia and former Executive Director of the TOGETHER Trial Consortium, intends to merge a new operating business under fresh management with the clean corporate platform.GurufocusBranded Legacy, Inc. Finalizes Transformative Acquisition of BioBranded Legacy, Inc. completed an acquisition of Bio Legacy Evaluative Group for $1.5 million in Preferred D stock, with a two-year lock-up and $1 million R&D commitment. The deal targets Bio Legacy's intranasal naloxone device, projected to grow the market to $1.16 billion by 2032, with potential revenues of $183.3 million by Year 5.GlobeNewswireBranded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold DevelopmentBranded Legacy, Inc. (OTC: BLEG), through its subsidiary BioLegacy Evaluative Group Inc., has initiated engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform. This milestone bridges concept to commercial manufacturing, enabling high-volume, cost-effective production aligned with pharmaceutical standards to deliver therapeutics including inhaled naloxone. Combined with a recent provisional patent filing and a new GMP-compliant manufacturing facility in Vancouver, this advancement positions the company to address public health challenges like the opioid crisis with affordable solutions.GlobeNewswireBranded Legacy, Inc. (OTC: BLEG) Advances Life-Saving Innovation with FDA Pre-ANDA Briefing for Revolutionary Intranasal Naloxone SprayBranded Legacy's subsidiary BioLegacy Evaluative Group began preparing its FDA Pre-ANDA briefing package for an intranasal naloxone spray. The package includes a Target Product Profile for 2mg and 4mg doses, a 60-subject bioequivalence study against Narcan, and a human factors study. The company seeks FDA guidance on study sufficiency and device requirements.GlobeNewswireBranded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics MarketBioLegacy, a subsidiary of Branded Legacy, filed a provisional patent with the USPTO for an air-driven intranasal drug delivery device. The device delivers stable or reconstitutable medicaments via a precision atomizer, targeting emergency and self-administered pharmaceuticals. The filing aligns with BioLegacy's GMP manufacturing facility and ongoing R&D collaborations.GlobeNewswireBranded Legacy Inc. Unveils Cutting-Edge GMP Facility to Accelerate Life-Saving Inhaled Naloxone DevelopmentBioLegacy Evaluative Group, a subsidiary of Branded Legacy, opened a 22,000-square-foot GMP facility in Vancouver, Canada. The facility supports development of inhaled naloxone devices to combat opioid overdoses, with partnerships at McMaster and Stanford universities. It also enables future pipeline expansion for vaccines and other medications.